ROS1 and non-small cell lung carcinoma: ROS1 kinase domain point mutations were detected predominantly in the dramatic progression group, while the activation of bypass and downstream pathways occurred in the gradual/local progression group.<h4>Conclusion</h4>The progression modes of ROS1 rearrangement may predict survival benefits and provide subsequent treatment strategies in ROS1-rearranged NSCLC.